Femasys (NASDAQ:FEMY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Femasys (NASDAQ:FEMY) from a sell rating to a hold rating in a research report report published on Friday morning.

Several other research analysts have also issued reports on the company. HC Wainwright decreased their price objective on Femasys from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Laidlaw started coverage on Femasys in a report on Thursday, November 20th. They set a “buy” rating and a $6.50 target price on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Femasys in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $6.83.

Femasys Stock Up 2.5%

Shares of NASDAQ:FEMY opened at $1.02 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.16 and a quick ratio of 0.61. The stock has a market cap of $59.36 million, a price-to-earnings ratio of -1.41 and a beta of -2.59. The company has a 50 day moving average of $0.69 and a 200-day moving average of $0.74. Femasys has a one year low of $0.31 and a one year high of $1.80.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.02. Femasys had a negative net margin of 960.80% and a negative return on equity of 764.26%. The business had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.35 million. On average, sell-side analysts forecast that Femasys will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Femasys

Several large investors have recently modified their holdings of the business. Osaic Holdings Inc. bought a new position in shares of Femasys during the 2nd quarter valued at about $45,000. Jane Street Group LLC acquired a new stake in Femasys during the 2nd quarter worth approximately $82,000. Finally, Clear Creek Financial Management LLC lifted its stake in Femasys by 4.2% in the second quarter. Clear Creek Financial Management LLC now owns 281,821 shares of the company’s stock valued at $272,000 after buying an additional 11,450 shares in the last quarter. 65.27% of the stock is currently owned by institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.